Mechanism of Action

MAPK Pathway

TAFINLAR + MEKINIST inhibits 2 points on the MAPK pathway, which is constitutively active in BRAF V600–mutated solid tumors^1,2

ERK, extracellular signal-related kinase; MAPK, mitogen-activated protein kinase; MEK, mitogen-activated extracellular signal-regulated kinase; RAS, monomeric G protein.

In the setting of BRAF-mutant colorectal cancer, induction of epidermal growth factor receptor–mediated MAPK pathway reactivation has been identified as a mechanism of intrinsic resistance to BRAF inhibitors.^1,2

NEXT: Access/Patient Support